Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for SUSTIVA
- Efavirenz for Patients With Alzheimer's Disease
- Pharmacokinetics of Efavirenz in the Presence of Rifampicin and Isoniazid
- Pharmacologic Strategies to Use the Levonorgestrel Implant in HIV-infected Women
- PK of Efavirenz & Lopinavir Nano-formulations in Healthy Volunteers
- SSAT063- Pharmacokinetics of Efavirenz 400 mg Once Daily During Pregnancy in HIV-1 Infected Women
- Efficacy of VHM After Treatment Interruption in Subjects Initiating ART During Acute HIV Infection
- PK Study of Rifampicin Interactions With DMPA and Efavirenz in TB
- CYP2B6 Genetics and Drug Interactions in Healthy Volunteers
- Multiple Dose Comparison of the Effect of Two Dose Combinations of Tipranavir/Ritonavir (TPV/RTV), on the Pharmacokinetic Characteristics of Efavirenz (Sustiva®) in Healthy Adult Volunteers
- Effects of Steady-state Efavirenz 600 mg QD (Sustiva®) on Tipranavir Concentration at Steady-state in Healthy Adult Volunteers
- Pharmacokinetics and Pharmacodynamics of the Etonogestrel Contraceptive Implant When Co-administered With Efavirenz
- Changes in Liver Steatosis After Switching to Raltegravir in HIV/HCV Coinfection
- EFV Pharmacokinetics & Pharmacogenomics in Older HIV-infected Patients
- A Pharmacokinetic Evaluation of Levonorgestrel Implant and Antiretroviral Therapy
- Pharmacokinetic Study of Pitavastatin and Ritonavir-Boosted Darunavir or Efavirenz
- Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r)
- A Drug-Drug Interaction Study Between Fenofibric Acid and Efavirenz
- Efficacy, Safety, and Tolerability of Cenicriviroc (CVC) in Combination With Truvada or Sustiva Plus Truvada in HIV 1-infected, Antiretroviral Treatment-naïve, Adult Patients Infected With Only CCR5-tropic Virus
- PI or NNRTI as First-line Treatment of HIV in West Africa - the PIONA Trial
- Hepatic Safety of Raltegravir Versus Efavirenz as HIV Therapy for Patients With HIV and HCV Coinfection
- Determine the Effects of Gene Differences and Voriconazole on Enzyme CYP2B6 Activity in the Liver in Healthy Volunteers
- GSK1349572 Drug Interaction Study With Efavirenz
- Sustiva Levels With Use of a Gel Capsule
- Cryptococcal Optimal ART Timing Trial
- Lopinavir/Ritonavir or Efavirenz as First-line Antiretroviral Therapy
- Safety, Tolerability, and Effect of TMC207 and Efavirenz in Healthy Volunteers
- Equivalence of Boosted Atazanavir Based Regimens and Currently Effective HAART Regimens
- A Pilot Project of Virologic, Pharmacologic and Immunologic Correlates of Gastrointestinal-Associated Lymphoid Tissue Immune Reconstitution Following Maraviroc Therapy
- Raltegravir Activity In Lymphoid Tissues
- Pharmacokinetic and Pharmacodynamic Interactions Between the Cholesterol-lowering Ezetimibe and the Non-nucleoside Reverse Transcriptase Inhibitor Efavirenz During Chronic Treatment in Healthy Volunteers With Reference to Intestinal Expression of CY
- A Feasibility Study of Co-administering Combination Antiretroviral Therapy (cART) and R-EPOCH Chemotherapy for the Management of ARL
- NNRTI/PI Toxicity Switch to Darunavir Study
- A Study in Underrepresented Patient Population or Regimen Tolerability: SUPPoRT
- Pharmacokinetic Interactions Between Antiretroviral Agents and Antimalarial Drug Combinations
- Effects of CYP2B6 Genetic Polymorphisms on Efavirenz Pharmacokinetics
- Pilot Project of Virologic and Immunologic Correlates of GALT Immune Reconstitution Following Raltegravir Therapy
- Clinical Trial of CNS-targeted HAART (CIT2)
- Drug Interaction Between Coartem® and Nevirapine, Efavirenz or Rifampicin in HIV Positive Ugandan Patients
- Pharmacokinetic Interactions Between Buprenorphine and Kaletra (Lopinavir/Ritonavir)
- Randomized Clinical Trial to Assess the Efficacy and Safety of Concomitant Use of Rifampicin and Efavirenz 600 X 800mg
- Safety, Tolerance, Pharmacokinetic and Antiviral Study of Amdoxovir in Combination With Zidovudine in Adults With HIV
- FOTO: Five Consecutive Days on Treatment With Efavirenz, Tenofovir, and Emtricitabine Followed by Two Days Off Treatment Versus Continuous Treatment
- Drug Interaction - Oral Contraceptive
- Safety, Tolerability and Pharmacokinetics of Efavirenz in HIV-Infected Children
- Elvucitabine/Efavirenz/Tenofovir vs. Lamivudine/Efavirenz/Tenofovir in HIV-1 Infected, Treatment Naive Subjects
- Safety and Durability ofTenofovir and a Cell Cycle Agent for Viral Suppression
- Antiretroviral Treatment Simplification Study With Efavirenz + Abacavir + 3TC Once Daily
- Study to Determine the Pharmacokinetic Behavior of Antiretroviral Drugs in Patients Infected by HIV
- Modification of Doses of Efavirenz According to Its Blood Concentration in HIV Patients
- Once a Day (QD) - Twice a Day (BID) Clinical Trial: Didanosine, Lamivudine and Efavirenz Versus Zidovudine, Lamivudine and Efavirenz in the Starting Treatment of HIV
- An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection
- An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection: Canada
- Pharmacokinetics of Efavirenz in HIV-1 Infected Subjects With Hepatic Impairment
- Study Switching HIV-1 Infected Patients With an Undetectable Viral Load on a First Protease Inhibitor-Based Regimen to an Efavirenz-Based Regimen
- A Study Exploring an Induction-Maintenance Kaletra-Based Therapy Versus a Sustiva-Based Regimen in Previously Non-Treated, HIV-1/HCV Co-Infected Subjects
- Tenofovir Disoproxil Fumarate/Emtricitabine/Efavirenz Versus Combivir/Efavirenz in Antiretroviral-Naive HIV-1 Infected Subjects
- A Simplified Kaletra® (Lopinavir/Ritonavir)-Based Therapy Versus a Sustiva® (Efavirenz)-Based Standard of Care in Previously Non-Treated HIV-Infected Subjects
- Preventing Sexual Transmission of HIV With Anti-HIV Drugs
- Effectiveness of ABT-378/Ritonavir Plus Lamivudine Plus Efavirenz Plus Tenofovir DF in HIV-Infected Patients
- Safety and Effectiveness of Emtricitabine, Efavirenz, and Didanosine in HIV Infected Children Who Have Taken Few or No Anti-HIV Drugs
- A Study to Determine How and Why HIV-Infected Subjects on Anti-viral Treatment Develop Lipodystrophy
- Effectiveness and Safety of Epivir/Ziagen/Zerit (3TC/ABC/d4T) Versus Epivir/Ziagen/Sustiva (3TC/ABC/EFV) Versus Epivir/Ziagen/Agenerase/Norvir (3TC/ABC/APV/RTV) in HIV Patients Who Have Never Received Treatment
- A Study of the Safety and Effectiveness of Combination Anti-HIV Therapy in HIV-Infected Adults
- A Study to Compare Two Anti-HIV Drug Combinations
- Safety and Effectiveness of Giving Adefovir Dipivoxil Plus Abacavir Plus Efavirenz Plus Amprenavir to HIV-Infected Patients Who Have Failed to Respond to Previous Protease Inhibitor Treatment
- A Study on the Safety and Effectiveness of Twice-Daily Nelfinavir Plus Twice-Daily Indinavir Plus Efavirenz in HIV-Positive Patients Who Have Never Taken Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) or Protease Inhibitors
- Safety and Effectiveness of Giving an Anti-HIV Drug Combination of Adefovir Dipivoxil Plus Didanosine Plus Efavirenz Plus Lamivudine Once Daily to HIV-Infected Patients
- Continued Antiretroviral Therapy With Abacavir, Amprenavir and Efavirenz
Clinical trials list
click for details